Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Increases By 337.2%

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 240,900 shares, a growth of 337.2% from the March 31st total of 55,100 shares. Based on an average daily trading volume, of 221,200 shares, the short-interest ratio is presently 1.1 days. Approximately 4.4% of the shares of the stock are sold short.

bioAffinity Technologies Stock Performance

Shares of NASDAQ BIAF traded up $0.01 during trading on Friday, reaching $2.42. The company had a trading volume of 92,544 shares, compared to its average volume of 181,516. The company’s fifty day moving average price is $2.17 and its 200-day moving average price is $1.72. The company has a current ratio of 1.77, a quick ratio of 1.76 and a debt-to-equity ratio of 0.17. bioAffinity Technologies has a 12 month low of $0.95 and a 12 month high of $3.62.

bioAffinity Technologies (NASDAQ:BIAF) last announced its earnings results on Monday, April 1st. The company reported ($0.26) EPS for the quarter. The firm had revenue of $2.21 million during the quarter. bioAffinity Technologies had a negative net margin of 313.34% and a negative return on equity of 107.20%.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.